The emergence of atypical response (AR) has challenged the process of response evaluation and the subsequent management of non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors. This evidence concerns the gene CD274 and non-small cell lung carcinoma.